COMMUNIQUÉS West-GlobeNewswire

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
19/05/2026
Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey [...]
BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
19/05/2026
SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate [...]
Brain Cancer Canada Invests $75,000 in Groundbreaking Glioblastoma Research at University of Alberta, Targeting How Tumours “Communicate”
19/05/2026
TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide, is proud to award $75,000 to a [...]
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
19/05/2026
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year’s awardees recently [...]
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
19/05/2026
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) ("Tiziana"), a biotechnology [...]
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
19/05/2026
Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or [...]
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
19/05/2026
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO’s introduction to the broader ophthalmology community at ASCRS drove strong [...]
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
19/05/2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that [...]
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
19/05/2026
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Demonstrated >90% editing of SERPINA1 [...]
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
19/05/2026
Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. ( [...]
XORTX Announces Closing of US$5 Million Public Offering
19/05/2026
CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
EyePoint Announces Participation at Upcoming Investor Conferences
19/05/2026
WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences
19/05/2026
CHICAGO, May 19, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio , a clinical-stage biopharmaceutical company, announced that the company will present interim data from its Phase 1b study at World Parkinson’s Congress and the GBA1 [...]
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
19/05/2026
– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – MELBOURNE, [...]
Science 37 and Tufts CSDD Publish Landmark Study on Direct-to-Patient Clinical Trial Site Performance, Outperforming Industry Benchmarks
19/05/2026
MORRISVILLE, N.C., May 19, 2026 (GLOBE NEWSWIRE) -- Science 37 today announced the publication of a new analysis in Applied Clinical Trials in collaboration with the Tufts Center for the Study of Drug Development (Tufts [...]
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
19/05/2026
- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Zenas [...]
ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium
19/05/2026
Garching / Munich, May 19 , 2026 –– ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that dosimetry data from its Phase 3 COMPETE trial will be provided in a [...]
Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium
19/05/2026
Geleen, May 19 th , 2026 Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced that the U.S. Food and Drug Administration (FDA) has cleared [...]
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
19/05/2026
Milestone advances commercial and manufacturing readiness ahead of anticipated pivotal study scale-up BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") ( [...]

Pages